Refine by
Vaccine Candidate Equipment & Supplies
43 equipment items found
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved. IVX-121 incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019). RSV F is known to undergo major structural changes that allow viral entry into the host cell, and during that process, critical protective epitopes are lost. Protein ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti-human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus. It is our hope that the drug candidate can ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-A12 is a bivalent combination of IVX-121 and IVX-241, a human metapneumovirus (hMPV) VLP vaccine candidate. IVX-A12 is being designed to target both RSV and hMPV in a single vaccine candidate. hMPV is being increasingly recognized as a major contributor to acute respiratory infection and pneumonia with rates of pneumonia ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing a live attenuated COVID-19 vaccine candidate, MV-014-212, to induce mucosal and systemic immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Like Meissa’s RSV vaccine candidate, MV-014-212 offers significant potential advantages for global deployment, including ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Icosavax has initiated development of IVX-421, a SARS-CoV-2 vaccine candidate that incorporates an RBD antigen with critical mutations found in the SARS-CoV-2 beta ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
The attenuation of a virus to produce a vaccine must balance reducing its virulence while retaining its ability to stimulate an effective immune response, or immunogenicity. Natural RSV infection does not stimulate a robust immune response, and immunity following SARS-CoV-2 infection wanes, so vaccine technologies that enhance immunogenicity are required. ...
Manufactured by:Vaxcyte, Inc. based inSan Carlos, CALIFORNIA (USA)
We believe our clinical-stage company is uniquely positioned to create vaccines that can overcome bacteria’s formidable defense mechanisms and be produced on a significant scale. We are leveraging our XpressCF™ cell-free protein synthesis platform to create high-fidelity vaccines featuring distinct protein carriers and antigens – the critical building blocks of vaccines ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. Emergence of new bacterial serotypes necessitate a new vaccination approach. Virometix is developing an epitope-based, serotype-independent, pneumococcal ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five Synthetic ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring ...
Manufactured by:FluGen, Inc. based inMadison, WISCONSIN (USA)
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen’s flu vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering unprecedented efficacy against infection and illness across seven years of virus drift, and ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...